In Brief: FDA Office of Generic Drugs
FDA Office of Generic Drugs: Recruiting nationally for a permanent office director, acting Director Doug Sporn tells the National Association of Pharmaceutical Manufacturers mid-year meeting June 21 in Washington, D.C. Sporn predicts permanent director will be in place in the first quarter of 1996. OGD is also recruiting for the Division of Chemistry II director position to be announced by the end of July...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth